I would be happy to answer that, Madam Chair.
I think that Dr. Bourguet, in describing the explosion of research in this area, reflects the importance of what the nuclear medicine community can do in terms of assisting our clinical colleagues as they make important clinical decisions and stratify patients for treatments. And in the future, I think, as Christopher said, we will be moving to the era of personalized medicine.
What is particularly important, and why I think the CIHR round is very important, is that it indicates that we're not only looking at how we deal with technetium products, how we find alternatives to our currents tests, but we're committing to that evolutionary path to the next generation of tests.
I had the privilege of being part of a working group with CIHR on medical imaging as well. So within that context, we're building a framework that is going to enable us to look not only at alternative ways of making technetium but at technetium replacements at the same time as we build a framework to do what Dr. Urbain and Dr. O'Brien have so eloquently pointed out, which is leading to the next generation of tests.